AbbVie Inc. (ABBV)

74.59
0.09 0.12
NYSE : Health Technology
Prev Close 74.50
Open 74.38
Day Low/High 74.34 / 74.98
52 Wk Low/High 62.66 / 94.98
Volume 3.10M
Avg Volume 8.68M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 109.05B
EPS 3.70
P/E Ratio 26.25
Div & Yield 4.28 (5.66%)
ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/14/2018 settlement date, and AbbVie Inc is one of the most shorted stocks of the Russell 3000, based on 7.73 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc.

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc.

The New #66 Most Shorted S&P 500 Component: AbbVie

The New #66 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

10 Top Stocks With a History of Double-Digit Dividend Growth

10 Top Stocks With a History of Double-Digit Dividend Growth

Searching for dividends in this yield starved world? Check out these top 10 names.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

The 5 Highest-Yielding 'Dividend Aristocrats'

This exclusive group of stocks is among the best when it comes to returning cash to shareholders and building wealth over time.

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

Blue Chip stocks are the way to go right now. Here are several key names worth considering.

Amazon Could Rise Another 15% From Here: Market Recon

Amazon Could Rise Another 15% From Here: Market Recon

This stock is still going wild after earnings.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

10 Large-Cap Stocks With At Least 40% Upside Potential

10 Large-Cap Stocks With At Least 40% Upside Potential

On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 06/15/2018 settlement date, and AbbVie Inc is the #146 most shorted of the S&P 500 components, based on 4.35 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Galapagos' new cystic fibrosis drug trial results were weaker than expected.

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

MedMen is now selling shares on the Canadian Securities Exchange. Here's why it still isn't possible for the $1.65 billion company to list in its home country.

AbbVie Becomes #233 Most Shorted S&P 500 Component, Replacing Mettler-Toledo International

The most recent short interest data has been released for the 05/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

TheStreet Quant Rating: C (Hold)